Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 23, 2026, 5:31 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 649–672 of 677 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Morning Group Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase I Study to Investigate the Effect of Renal Impairment on the Pharmacokinetics, Safety, and Tolerability of AZD0780

NCT06592482
View directory record Official record
Conditions
Renal Impairment
Interventions
AZD0780
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 85 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
5
States / cities
Lake Forest, California • Hialeah, Florida • Orlando, Florida + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 20, 2025 · Synced Oct 23, 2026, 5:31 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Caries Prevention Products & Dentinal Hypersensitivity

NCT02136576
View directory record Official record
Conditions
Hypersensitivity
Interventions
Sensodyne, Crest Cavity Protection & MI Paste Plus, Clinpro 5000
Device
Lead sponsor
Tufts University
Other
Eligibility
18 Years and older
Enrollment
39 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2018
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 10, 2020 · Synced Oct 23, 2026, 5:31 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

The Effects of Early and Late Time-Restricted Feeding on Body Composition

NCT04000516
View directory record Official record
Conditions
Time Restricted Feeding
Interventions
Time restricted feeding
Behavioral
Lead sponsor
Texas Tech University
Other
Eligibility
19 Years to 55 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
1
States / cities
Lubbock, Texas
Source: ClinicalTrials.gov public record
Updated Jun 27, 2019 · Synced Oct 23, 2026, 5:31 AM EDT
Completed Early Phase 1 Interventional

Mediators of Abnormal Reproductive Function in Obesity (MARO)

NCT01817400
View directory record Official record
Conditions
Infertility, Female, Obesity
Interventions
Microdialysis, Vascepa - Fish Oil, Aspirin, Pioglitazone
Other · Dietary Supplement · Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 60 Years · Female only
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Mar 17, 2015 · Synced Oct 23, 2026, 5:31 AM EDT
Recruiting Phase 3 Interventional

The Effect of Bacterial Decolonization Before Skin Cancer Surgery on Infection Rate of Lower Extremity Wounds Left Open to Heal

NCT07142408
View directory record Official record
Conditions
Surgical Wound Infection
Interventions
Chlorhexidine gluconate (4%), Mupirocin 2% Ointment
Drug
Lead sponsor
The Cooper Health System
Other
Eligibility
18 Years and older
Enrollment
848 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2030
U.S. locations
1
States / cities
Marlton, New Jersey
Source: ClinicalTrials.gov public record
Updated Aug 26, 2025 · Synced Oct 23, 2026, 5:31 AM EDT
Completed Phase 3 Interventional Results available

A Phase III Parallel Group Study, Comparing the Efficacy, Safety and Tolerability of the Fixed Dose Combination (FDC) of Fluticasone Furoate+Umeclidinium Bromide+Vilanterol (FF/UMEC/VI) With the FDC of FF/VI in Subjects With Inadequately Controlled Asthma

NCT02924688
View directory record Official record
Conditions
Asthma
Interventions
FF/UMEC/VI (100/31.25/25) mcg, FF/UMEC/VI (100/62.5/25) mcg, FF/UMEC/VI (200/31.25/25) mcg, FF/UMEC/VI (200/62.5/25) mcg, FF/VI (100/25) mcg, FF/VI (200/25) mcg, Fluticasone/salmeterol (FSC), Albuterol/salbutamol, ELLIPTA DPI, DISKUS DPI, METERED-DOSE INHALER (MDI)
Drug · Device
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
2,436 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
99
States / cities
Birmingham, Alabama • Mobile, Alabama • Montgomery, Alabama + 89 more
Source: ClinicalTrials.gov public record
Updated Mar 26, 2021 · Synced Oct 23, 2026, 5:31 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Study of PER977 Administered to Subjects With Steady State Edoxaban Dosing and Re-anticoagulation With Edoxaban

NCT02207257
View directory record Official record
Conditions
Anticoagulation Reversal
Interventions
PER977, Placebo, Edoxaban
Drug
Lead sponsor
Perosphere Pharmaceuticals Inc, a wholly owned subsidiary of AMAG Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
65 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated May 21, 2020 · Synced Oct 23, 2026, 5:31 AM EDT
Completed No phase listed Observational

Aromatase Inhibitor-Associated Musculoskeletal Symptoms in Non-Metastatic, Post Menopausal Breast Cancer Patients

NCT01051609
View directory record Official record
Conditions
Breast Cancer
Interventions
History and Physical Exam, Grip Strength Measurement, Surveys, Blood Collection, Ultrasound of Hand/Wrist
Other · Behavioral · Procedure
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2010
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Sep 9, 2016 · Synced Oct 23, 2026, 5:31 AM EDT
Terminated Phase 2 Interventional Results available

Efficacy and Safety of MK-1942 When Added to Stable Antidepressant Therapy in Participants With Treatment-Resistant Depression (TRD) (MK-1942-006)

NCT04663321
View directory record Official record
Conditions
Treatment Resistant Depression
Interventions
MK-1942, Placebo
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years to 65 Years
Enrollment
99 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
45
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Bellflower, California + 40 more
Source: ClinicalTrials.gov public record
Updated May 4, 2026 · Synced Oct 23, 2026, 5:31 AM EDT
Completed Not applicable Interventional Results available

PEMF Therapy to Treat Interstitial Cystitis/Bladder Pain Syndrome

NCT04540887
View directory record Official record
Conditions
Interstitial Cystitis, Chronic Interstitial Cystitis, Bladder Pain Syndrome
Interventions
Pulsed Electromagnetic Field (PEMF) Therapy
Device
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years to 80 Years · Female only
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Dec 5, 2022 · Synced Oct 23, 2026, 5:31 AM EDT
Withdrawn Not applicable Interventional

Benefits of Nutritional Ingredients for Type 2 Diabetes

NCT06327711
View directory record Official record
Conditions
Diabetes type2
Interventions
Control: CHO Blend, Experimental: CHO Blend plus AN100
Other
Lead sponsor
Abbott Nutrition
Industry
Eligibility
40 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Kent, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 4, 2024 · Synced Oct 23, 2026, 5:31 AM EDT
Completed Phase 2 Interventional Results available

Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder

NCT00481195
View directory record Official record
Conditions
Bipolar I Depression
Interventions
Armodafinil, Placebo
Drug
Lead sponsor
Cephalon
Industry
Eligibility
18 Years to 65 Years
Enrollment
257 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
42
States / cities
Birmingham, Alabama • Escondido, California • Lafayette, California + 35 more
Source: ClinicalTrials.gov public record
Updated Jul 19, 2013 · Synced Oct 23, 2026, 5:31 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Evaluation of a Remote Training Strategy

NCT05039164
View directory record Official record
Conditions
Behavior Disorders
Interventions
Coping Power Program (CPP), CBT for Anxiety Treatment in Schools (CATS), Check-in/Check-out (CI/CO), Initial Training (CC), Initial Training plus Video (RV), Initial Training plus Video plus Coaching (RV+)
Behavioral
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
8 Years to 99 Years
Enrollment
140 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2025
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 15, 2025 · Synced Oct 23, 2026, 5:31 AM EDT
Completed Phase 3 Interventional Results available

Ranolazine When Added to Glimepiride in Subjects With Type 2 Diabetes Mellitus

NCT01494987
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
Ranolazine, Placebo, Glimepiride, Diet, Exercise
Drug · Behavioral
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 75 Years
Enrollment
431 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
46
States / cities
Mesa, Arizona • Tucson, Arizona • Pine Bluff, Arkansas + 39 more
Source: ClinicalTrials.gov public record
Updated Nov 18, 2014 · Synced Oct 23, 2026, 5:31 AM EDT
Recruiting Phase 2 Interventional Accepts healthy volunteers

Tirzepatide: Reversal of Lipotoxicity and Adipose Tissue Dysfunction in Humans With Overweight/Obesity

NCT05912621
View directory record Official record
Conditions
Obesity, Overweight and Obesity, Overweight
Interventions
Tirzepatide
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 70 Years
Enrollment
66 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2029
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Dec 4, 2024 · Synced Oct 23, 2026, 5:31 AM EDT
Completed Not applicable Interventional Results available

A Pharmacist Intervention for Monitoring and Treating Hypertension Using Bidirectional Texting

NCT03986931
View directory record Official record
Conditions
Hypertension
Interventions
Experimental: Pharmacist-Bidirectional Texting Group, Active Comparator: Control Group
Other
Lead sponsor
Linnea Polgreen
Other
Eligibility
21 Years to 100 Years
Enrollment
535 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Jan 22, 2025 · Synced Oct 23, 2026, 5:31 AM EDT
Completed Not applicable Interventional

Safety and Efficacy of Transcranial Electromagnetic Treatment Against Alzheimer's Disease

NCT02958930
View directory record Official record
Conditions
Alzheimer Disease, Alzheimer Disease, Late Onset
Interventions
MemorEM 1000
Device
Lead sponsor
NeuroEM Therapeutics, Inc.
Industry
Eligibility
63 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Apr 23, 2019 · Synced Oct 23, 2026, 5:31 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Enhanced Stress Resilience Training for Residents

NCT03518359
View directory record Official record
Conditions
Stress, Mindfulness, Cognitive Change
Interventions
Enhanced Stress Resilience Training (ESRT), Active Control
Behavioral
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 64 Years
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2021
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Feb 24, 2022 · Synced Oct 23, 2026, 5:31 AM EDT
Completed Phase 1 Interventional

Safety, Tolerability, and Pharmacokinetics of Oral NX-13 in Active Ulcerative Colitis

NCT04862741
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
NX-13 250mg IR, NX-13 500mg IR, NX-13 500mg MR, Placebo
Drug
Lead sponsor
Landos Biopharma Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
22
States / cities
Huntsville, Alabama • Lancaster, California • Mission Viejo, California + 18 more
Source: ClinicalTrials.gov public record
Updated Feb 15, 2023 · Synced Oct 23, 2026, 5:31 AM EDT
Terminated Phase 2 Interventional Results available

LiftActiv B3 in Post Inflammatory Hyperpigmentation (PIHP)

NCT05327361
View directory record Official record
Conditions
Acne, Post Inflammatory Hyperpigmentation
Interventions
Liftactiv B3, Sunscreen
Drug · Other
Lead sponsor
University of Miami
Other
Eligibility
18 Years to 50 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Apr 3, 2024 · Synced Oct 23, 2026, 5:31 AM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Adherence to Health Coaching with Wearable Devices: Enhancing Patient Engagement and Outcomes

NCT06525337
View directory record Official record
Conditions
Obstructive Sleep Apnea
Interventions
STANDARDCARE (STAND) group, CONTROL (CON) group
Behavioral · Other
Lead sponsor
Coastal Carolina University
Other
Eligibility
18 Years to 85 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
2
States / cities
Conway, South Carolina • Cordova, Tennessee
Source: ClinicalTrials.gov public record
Updated Dec 9, 2024 · Synced Oct 23, 2026, 5:31 AM EDT
Completed Phase 2 Interventional Results available

Phase IIb Study of Umeclidinium (UMEC) Bromide Versus Placebo in Subjects With Asthma

NCT03012061
View directory record Official record
Conditions
Asthma
Interventions
Placebo, UMEC, Fluticasone Furoate, Albuterol/salbutamol
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
425 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
19
States / cities
Tempe, Arizona • Rolling Hills Estates, California • Colorado Springs, Colorado + 15 more
Source: ClinicalTrials.gov public record
Updated Oct 28, 2020 · Synced Oct 23, 2026, 5:31 AM EDT
Completed Phase 3 Interventional Results available

Multicenter Randomized Parallel Group Phase III Study Comparing the Bowel Cleansing Efficacy, Safety and Tolerability of NER1006 Versus Trisulfate Solution Using 2-Day Split-Dosing Regimen in Adults

NCT02254486
View directory record Official record
Conditions
Colon Cancer, Colorectal Carcinoma, Colon Cleansing
Interventions
NER1006, Trisulfate solution
Drug
Lead sponsor
Norgine
Industry
Eligibility
18 Years to 85 Years
Enrollment
621 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
12
States / cities
Anaheim, California • Annapolis, Maryland • Chevy Chase, Maryland + 9 more
Source: ClinicalTrials.gov public record
Updated May 15, 2018 · Synced Oct 23, 2026, 5:31 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Safety and Efficacy of Linaclotide in Patients With Chronic Constipation and Prominent Abdominal Bloating

NCT01642914
View directory record Official record
Conditions
Chronic Constipation, Constipation
Interventions
Linaclotide 290 micrograms, Linaclotide 145 micrograms, Matching placebo
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
18 Years and older
Enrollment
487 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
146
States / cities
Chandler, Arizona • Glendale, Arizona • Goodyear, Arizona + 125 more
Source: ClinicalTrials.gov public record
Updated Apr 26, 2016 · Synced Oct 23, 2026, 5:31 AM EDT